Drugs / HPV-16/18 L1/AS04
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT00290277 | Nov 2005 → Aug 2006 | human papilloma virus infection | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HPV-16/18 L1/AS04 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00290277 ↗ |
| Modality | Vaccine | “HPV vaccine” NCT00290277 ↗ |
| Route | Intramuscular | “Vaccine Administered Intramuscularly” NCT00290277 ↗ |